




- (51) **International Patent Classification:**
A61K 35/17 (2015.01) *C12N 5/0786* (2010.01)
- (21) **International Application Number:**
PCT/US2023/017002
- (22) **International Filing Date:**
30 March 2023 (30.03.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/325,439 30 March 2022 (30.03.2022) US
- (71) **Applicant: MDX MANAGEMENT LLC [US/US];** 9046 La Jolla Shores Lane, La Jolla, California 92037 (US).
- (72) **Inventors: LIU, Yuan;** 1150 Gavinwood Place, Decatur, Georgia 30033 (US). **BIAN, Zhen;** 76 Staley Drive, Tucker, Georgia 30084 (US). **SHI, Lei;** 702 Avondale Hill Drive, Decatur, Georgia 30032 (US). **STYLLI, Harry;** 9046 La Jolla Shores Lane, La Jolla, California 92037 (US).
- (74) **Agent: YOU, Yuying et al.;** Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) **Title:** COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS



(57) **Abstract:** The present application provides compositions and methods for producing antigen presenting cells (APCs) from monocytes (*e.g.*, monocytes from cancer patients) that involve an IL-10 receptor activator (*e.g.*, IL-10), IFN γ receptor activator (*e.g.*, IFN γ), TNF α receptor activator (*e.g.*, TNF α), IL-4 receptor activator (*e.g.*, IL-4), GM-CSF receptor activator (*e.g.*, GM-CSF), and/or IL-6 receptor activator (*e.g.*, IL-6). APCs produced accordingly are also provided, as well as methods of activating immune cells (*e.g.*, T cells) via co-culturing with APCs. The activated immune cell compositions and the methods of treatments that involve the activated immune cells are also provided.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*